Document is current
Any future updates will be listed below
-
Authors
Herter, Sonja
Emperador, Marta https://orcid.org/0000-0002-8538-4319
Smyrilli, Kyriaki
Kocher, Daniela https://orcid.org/0009-0007-0235-1081
Celikyürekli, Simay
Zeiser, Constantia
Gerloff, Xenia
Kreth, Sina
Henrich, Kai-Oliver
Maaß, Kendra K.
Rettenmeier, Johanna
Grünewald, Thomas G. P. https://orcid.org/0000-0003-0920-7377
Peterziel, Heike https://orcid.org/0000-0001-9261-7144
Westermann, Frank https://orcid.org/0000-0003-1584-3636
Hamacher-Brady, Anne https://orcid.org/0000-0001-5042-1338
Witt, Olaf
Oehme, Ina https://orcid.org/0000-0002-0827-2356
- License Information
-
More Information
Article History
Received: 1 November 2024
Revised: 8 July 2025
Accepted: 30 July 2025
First Online: 25 August 2025
Competing interests
: OW participated in advisory boards of Novartis, BMS, Janssen and receives research grants from BVD, Day One Therapeutics. IO receives research grants from PreComb, BVD and Day One Therapeutics.
